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Abstract: In the central nervous system, cystine import in exchange for 
glutamate through system xc− is critical for the production of the antioxidant 
glutathione by astrocytes, as well as the maintenance of extracellular 
glutamate. Therefore, regulation of system xc− activity affects multiple 
aspects of cellular physiology and may contribute to disease states. Pituitary 
adenylate cyclase-activating polypeptide (PACAP) is a neuronally-derived 
peptide that has already been demonstrated to modulate multiple aspects of 
glutamate signaling suggesting PACAP may also target activity of cystine-
glutamate exchange via system xc−. In the current study, 24-hour treatment 
of primary cortical cultures containing neurons and glia with PACAP 
concentration-dependently increased system xc− function as measured by 
radiolabeled cystine uptake. Furthermore, the increase in cystine uptake was 
completely abolished by the system xc− inhibitor, (S)-4-carboxyphenylglycine 
(CPG), attributing increases in cystine uptake specifically to system xc− 
activity. Time course and quantitative PCR results indicate that PACAP 
signaling may increase cystine-glutamate exchange by increasing expression 
of xCT, the catalytic subunit of system xc−. Furthermore, the potentiation of 
system xc− activity by PACAP occurs via a PKA-dependent pathway that is not 
mediated by the PAC1R, but rather the shared vasoactive intestinal 
polypeptide receptor VPAC1R. Finally, assessment of neuronal, astrocytic, and 
microglial-enriched cultures demonstrated that only astrocyte-enriched 
cultures exhibit enhanced cystine uptake following both PACAP and VIP 
treatment. These data introduce a novel mechanism by which both PACAP 
and VIP regulate system xc− activity. 
Keywords: PACAP, VIP, system xc−, astrocyte 
1. Introduction 
In the central nervous system (CNS) cystine-glutamate exchange is 
critical for the maintenance of extracellular glutamate concentrations 
(Baker et al., 2002; Moran et al., 2005; Murphy and Baraban, 1990), 
as well as supplying cystine to astrocytes for glutathione production 
(Kranich et al., 1998; Sagara et al., 1993). The cystine-glutamate 
antiporter, system xc−, composed of the light chain xCT and heavy 
chain 4F2hc subunits, is a sodium independent amino acid transporter 
that exchanges one molecule of extracellular cystine for one molecule 
of intracellular glutamate (Bannai, 1986; Bannai and Kitamura, 1980; 
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Sato et al., 1999). Nonvesicular extrasynaptic glutamate release by 
system xc− expressed on astrocytes may be important for activation of 
extrasynaptic NMDA and group II/III metabotropic glutamate 
receptors that, in turn, affect neuronal excitability (Kupchik et al., 
2012; Moran et al., 2005; Pow, 2001). In support, nonvesicular 
glutamate released by the cystine-glutamate antiporter is reported to 
be an essential regulator of extrasynaptic glutamate concentrations in 
the CNS (Baker et al., 2002). Moreover, dysregulation of extrasynaptic 
glutamate concentrations resulting from altered system xc− activity has 
been implicated in glutamate excitotoxicity (Piani and Fontana, 1994) 
and psychiatric disorders (Baker et al., 2008; Baker et al., 2003). With 
the large array of pathological states in the CNS stemming from both 
insufficient glutathione synthesis and dysfunctional glutamate 
homeostasis, system xc− is positioned to heavily influence a variety of 
pathologies ranging from compulsive disorders to neurodegenerative 
disease (Berman et al., 2011; de Groot and Sontheimer, 2011; Grant 
et al., 2007; Grant et al., 2009; Knackstedt et al., 2009; Park et al., 
2004; Sontheimer, 2011; Zhou and Kalivas, 2008). Unfortunately, the 
regulation of this heterodimeric amino acid transporter is poorly 
understood. 
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 
pleiotropic neuropeptide with widespread expression throughout the 
central nervous system (CNS) and periphery (Ghatei et al., 1993; 
Hannibal, 2002; Vaudry et al., 2009). In the CNS, substantial evidence 
has linked PACAP signaling to glutamate neurotransmission through its 
modulation of the ionotropic glutamate receptors NMDA and AMPA 
(Chen et al., 1999; Costa et al., 2009; Macdonald et al., 2005; Yaka et 
al., 2003). Furthermore, all PACAP receptors, including the high 
affinity PAC1 receptor as well as the vasoactive intestinal polypeptide 
(VIP) receptors VPAC1 and VPAC2, are reportedly expressed on 
astrocytes (Ashur-Fabian et al., 1997; Grimaldi and Cavallaro, 1999; 
Grimaldi and Cavallaro, 2000; Masmoudi-Kouki et al., 2007; Suzuki et 
al., 2003; Tatsuno et al., 1991) suggesting a significant involvement of 
PACAP signaling in the regulation of astrocyte function. This notion is 
further supported by PACAP treatment of primary astrocyte cultures 
producing increased expression and function of the glial glutamate 
transporters GLT-1 and GLAST (Figiel and Engele, 2000), which are 
needed for clearance of vesicular glutamate released by neurons from 
the synapse in order to prevent spillover of synaptic glutamate into 
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extrasynaptic areas (Asztely et al., 1997; Diamond and Jahr, 2000; 
Zheng et al., 2008). Importantly, PACAP synthesis and transmission 
may be exclusively released from glutamate neurons in the CNS 
(Fahrenkrug and Hannibal, 2004; Hannibal et al., 2000) allowing 
PACAP to have a potential modulatory role on glutamate signaling at 
both the neuron as well as on the surrounding glia. 
While PACAP appears to be a critical signal for astrocytes 
(Masmoudi-Kouki et al., 2007), as well as a key modulator of 
glutamate signaling (Magistretti et al., 1998), the affects of PACAP 
signaling on system xc− function are unknown. To test whether PACAP 
may regulate the activity of the cystine-glutamate antiporter we 
performed radiolabeled cystine uptake assays in primary cortical 
cultures following PACAP treatment. System xc− activity was 
potentiated following 24-hour treatment with PACAP and subsequent 
experiments were performed to determine the specific mechanism 
mediating the increased cystine-glutamate exchange produced by 
PACAP application in these cultures. 
2. Materials and Methods 
2.1 Materials 
Timed pregnant female Swiss Webster mice (Charles River 
Laboratories; Wilmington, DE) were housed in a climate-controlled 
room with a 12 hr light/dark cycle. Animals had free access to 
standard diet (Harlan 8604 formulation) and water until preparation of 
cell cultures. All procedures using animals were approved by the 
Marquette University Institutional Animal Care and Use Committee. 
PACAP was obtained from California Peptide Research (Napa, CA), 
PACAP6-38 from Anaspec (Fremont, CA), and VIP, VIP6-28, PG 97-
269, PG 99-465 from Bachem (Torrance, CA). (S)-4-
carboxyphenyglycine (CPG) was purchased from Tocris Bioscience 
(R&D Systems; Minneapolis, MN), and H89 from Sigma (St. Louis, 
MO). All other common chemicals were purchased from Sigma (St. 
Louis, MO). 
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2.2 Cortical cell cultures 
Primary mixed cortical cultures containing both neurons and glia 
were prepared from embryonic day 15–16 mouse pups as previously 
described (Lobner, 2000). Dissociated cortical cells suspended in 
Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied 
glutamine-free) supplemented with 5% heat-inactivated horse serum 
(Atlanta Biologicals; Lawrenceville, GA), 5% fetal bovine serum 
(Atlanta Biologicals), 2 mM glutamine and glucose (total 21 mM) were 
plated on 24-well plates coated with poly-D-lysine and laminin. 
Neuronal-enriched cultures were prepared in an identical manner with 
the addition of 10 µM cytosine arabinoside 48 hours after plating 
cultures in order to inhibit glial replication. Neuronal-enriched cultures 
using this method have astrocyte levels of <1% of the total cell 
population (Dugan et al., 1995; Rush et al., 2010). Astrocyte-enriched 
glial cultures were prepared using a similar protocol to that of the 
mixed cortical culture, however cortices were obtained from postnatal 
day 1–3 mouse pups (Choi et al., 1987; Rush et al., 2010; Schwartz 
and Wilson, 1992). To obtain microglial cultures, microglia were 
collected after shaking astrocyte-enriched glial cultures and then 
plated in media containing 10 ng/ml colony stimulating factor (CSF) 
(Barger and Basile, 2001). All cultures were maintained in humidified 
5% CO2 incubators at 37°C. 
2.3 Radiolabeled cystine uptake 
Radiolabeled cystine uptake was measured as previously 
described (Liu et al., 2014; Liu et al., 2012; Liu et al., 2009; Rush et 
al., 2012). Briefly, prior to treatment on in vitro day 15, cultures were 
washed in serum-free media and incubated for a specified period with 
or without drug. Following incubation, cultures were then washed with 
HEPES buffered saline solution and immediately exposed to 0.3 µM 
14C-cystine (Perkin Elmer; Waltham, MA) for 20 minutes. This 
concentration of 14C-cystine was used in order to simulate the 
estimated level of extracellular cystine found in the brain (Baker et al., 
2003). Following 14C-cystine exposure the cultures were washed with 
HEPES buffered saline solution and dissolved in 250 µl of 0.1% sodium 
dodecyl sulfate. Of the 250 µl sample, 200 µl were used for 
scintillation counting, with the remaining sample used for protein 
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quantification using the Bio-Rad DC protein assay (Hercules, CA). 
Counts were normalized protein concentration in each well and 
expressed as a percentage of 14C-cystine uptake in controls on the 
same experimental plate. For experiments using CPG, 200 µM CPG was 
added to the 14C-cystine solution during the 20 minute uptake 
experiment. 
2.4 Quantitative reverse transcription PCR 
Cultures used for qRT-PCR were treated the same as for 
radiolabeled cystine uptake assays. However, following drug 
incubation, cells were harvested for total RNA extraction using TRiZOL 
(Life Technologies; Grand Island, NY). Single-stranded cDNA synthesis 
was performed with 1 µg total RNA using the Promega Reverse 
Transcription System (Madison, WI). Real-time quantitative PCR was 
performed with the StepOne real-time PCR system (Applied 
Biosystems; Carlsbad, CA) using PerfeCTa SYBR Green FastMix 
containing ROX (Quanta Biosciences; Gaithersberg, MD). Relative 
quantification of xCT transcripts was analyzed via the ∆∆Ct method 
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Primers for each gene were designed to span an exon-exon junction 
and had efficiencies of approximately 95%. Product sizes for each 
primer set were 88 bp for xCT and 116 bp for GAPDH. Melt curve 
analysis of experiments confirmed a single product for each reaction. 
Primer sequences were as follows: xCT forward – AGG GCA TAC TCC 
AGA ACA CG; xCT reverse – GAC AGG GCT CCA AAA AGT GA; GAPDH 
forward – AAG GGC TCA TGA CCA CAG TC; and GAPDH reverse – GGA 
TGC AGG GAT GAT GTT CT. 
2.5 Statistics 
Data are presented as means ± standard errors of the mean, and were 
analyzed statistically by analysis of variance. Fischer LSD analysis was 
used for all post-hoc group comparisons. Statistical analyses were 
performed using Sigma Plot 11 software (Systat Software Inc.; San 
Jose, CA). P < 0.05 were considered statistically significant. 
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3. Results 
The effect of PACAP on system xc− activity was initially tested in 
primary mixed cortical cultures following 24-hour treatment of PACAP 
using concentrations ranging from 0.01 to 10 nM. Radiolabeled cystine 
uptake was significantly increased only at a concentration of 1 nM 
PACAP (Fig. 1A; P < 0.01). Consequently, we used the 1 nM 
concentration of PACAP for all future experiments examining cystine 
uptake following PACAP treatment unless otherwise stated. To 
determine whether the increased cystine uptake induced by PACAP 
could be attributed completely to increased system xc− activity, we co-
applied the system xc− inhibitor CPG (200 µM) with the radiolabeled 
cystine during uptake experiments, as the use of CPG for inhibition of 
system xc− has been used previously in a similar manner without 
negatively affecting cell viability (Fogal et al., 2007; Liu et al., 2014; 
Liu et al., 2012). CPG inhibited approximately 90% of radiolabeled 
cystine uptake in control cells as well as the increase in system xc− 
activity following 24-hour PACAP treatment (Fig. 1B; P < 0.05). 
 
Figure 1. PACAP increases cystine uptake through system xc− in a concentration-
dependent manner. (A) Concentration response of 24-hour PACAP treatment on 
primary mixed cortical cultures on radiolabeled cystine uptake (n = 6–12). (B) 
Inhibition of system xc− with (S)-4-carboxyphenylglycine (CPG; 200 µM) blocks cystine 
uptake in both control and PACAP (1 nM) treated primary mixed cortical cultures (n = 
4–12). Data are expressed as mean ± SEM. * = P < 0.05 compared to control group.  
To determine the optimal incubation period for PACAP treatment 
needed to augment system xc− activity, mixed cortical cultures were 
incubated with 1 nM PACAP for 1, 3, 6, 12, and 24 hours prior to the 
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radiolabeled cystine uptake assay. PACAP treatment produced 
significant increases in cystine uptake following incubation times 
ranging from 6–24 hours (Fig 2A; P < 0.05). The necessity for long-
term treatment with PACAP to significantly increase cystine uptake in 
primary mixed cortical cultures suggests that PACAP may be involved 
with the transcriptional regulation of the cystine-glutamate antiporter. 
Using quantitative real-time PCR (qPCR) we measured mRNA 
expression of the catalytic subunit of system xc−, xCT. Relative 
quantification for xCT mRNA was performed on total RNA extracted 
from control or PACAP-treated primary mixed cortical cultures for 24 
hours normalized to the housekeeping gene GAPDH. PACAP treatment 
for 24 hours produced significantly increased xCT mRNA levels in these 
cultures (Fig. 2B; P < 0.01). 
 
Figure 2. Time course of cystine uptake and quantitative PCR for xCT mRNA 
expression following PACAP treatment. (A) A time course revealed a delayed effect of 
PACAP (1nM) on cystine uptake in primary mixed cortical cultures. PACAP treatment 
for 6, 12, and 24 hours yielded significant increases in radiolabeled cystine uptake (n 
= 6–8). (B) Quantitative PCR from RNA isolated from control and 24-hour PACAP (1 
nM) treated primary mixed cortical cultures (n = 7–8). Data are expressed as mean ± 
SEM. * = P < 0.05 compared to control group. 
PACAP signaling through its G protein-coupled receptors often 
utilizes Gαs to increase adenylyl cyclase, a process leading to cyclic 
AMP formation and increased activation of protein kinase A (PKA) 
(Dickson and Finlayson, 2009). To determine whether the PKA 
pathway contributed to augmented system xc− activity by PACAP, 
mixed cortical cultures were treated with 10 µM H89 (Figiel and 
Engele, 2000), a PKA inhibitor, during the 24-hour PACAP treatment. 
Inhibition of PKA activity by H89 completely blocked the increase in 
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radiolabeled cystine uptake induced by PACAP treatment (Fig. 3; P < 
0.05). 
 
Figure 3. PACAP increases cystine uptake via a PKA-dependent pathway. 10 µM of 
the PKA inhibitor H89 completely blocked increases in cystine uptake induced by 24-
hour PACAP (1 nM) treatment in primary mixed cortical cultures (n = 8–16). Data are 
expressed as mean ± SEM. * = P < 0.05 compared to control group. 
To identify the PACAP receptor type mediating the effects on 
cystine-glutamate exchange, cortical cultures were co-incubated with 
antagonists for the PAC1 receptor or VPAC receptors. Inhibition of the 
PAC1 receptor with 100 nM PACAP6-38 did not block PACAP facilitated 
radiolabeled cystine uptake, but instead potentiated the effects of 
PACAP treatment alone (Fig 4A; P < 0.05 compared to PACAP 
treatment). The nonspecific VPAC receptor antagonist VIP6-28 at a 
concentration of 100 nM was effective in attenuating the increased 
cystine uptake following 24 hour 1 nM PACAP treatment (Fig. 4B; P < 
0.05). To further investigate which VPAC receptors were involved in 
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the augmentation of system xc− activity, primary mixed cortical 
cultures were pre-treated with specific antagonists for VPAC1R and 
VPAC2R. A 100 nM concentration of the VPAC1R antagonist PG 97-269 
blocked the increased cystine uptake produced by 24 hour PACAP (1 
nM) treatment in mixed cortical cells (Fig. 4C; P < 0.05), while similar 
treatment with the VPAC2R antagonist PG 99-465 had no effect (Fig. 
4D; P < 0.05). Finally, a concentration response using VIP 
concentrations ranging from 1, 10, and 100 nM also produced 
significant increases in radiolabeled cystine uptake (Fig. 4E; P < 0.05). 
To isolate which cell type in a mixed cortical culture preparation 
primarily contributed to the increased radiolabeled cystine uptake 
following incubation with PACAP or VIP, we performed similar assays 
using neuronal, astrocyte, and microglia-enriched cultures. Optimal 
concentrations determined from previous concentration response 
experiments in mixed cortical cultures resulted in the use of 1 nM 
PACAP (Fig. 1A) and 10 nM VIP (Fig. 4E) concentrations to test cell 
type specific effects on cystine uptake. Incubation with either PACAP or 
VIP produced significant increases in radiolabeled cystine uptake in 
astrocyte-enriched cultures only (Fig. 5B; P < 0.01), with no changes 
detected in neuronal or microglia-enriched cultures. Furthermore, 
vehicle treatment of astrocyte-enriched glial cultures exhibited much 
higher radiolabeled cystine uptake (6.48 ± 0.33 cpm/µg protein) 
compared to vehicle treated neuronal (1.54 ± 0.07 cpm/µg protein) 
and microglial-enriched (2.45 ± 0.30 cpm/µg protein) cultures. 
Increased concentrations of PACAP (10 nM) and VIP (100 nM) included 
in astrocyte-enriched culture experiments from Figure 5B also 
produced significantly increased cystine uptake (Fig. 6; P < 0.05). 
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Figure 4. Increases in cystine uptake induced by PACAP are mediated by the 
VPAC1R. (A) The PAC1R antagonist PACAP6-38 (100 nM) caused a potentiation of 1 
nM PACAP on cystine uptake (n = 16–24). (B) The VIP receptor antagonist VIP6-28 
(100 nM) significantly attenuated the increased cystine uptake caused by PACAP 
treatment (n = 7–16). (C) Treatment with 100 nM PG 97-269 (specific VPAC1R 
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antagonist) abolished the 1 nM PACAP effect on cystine uptake (n = 8–16), while (D) 
100 nM PG 99-465 (VPAC2R antagonist) had no effect (n = 8–12). (E) A concentration 
response of 24-hour VIP treatment showed that VIP increases cystine uptake at a 
similar concentration to PACAP, as well as at the higher concentration ranges where 
PACAP was ineffective (n = 8–16). Data are expressed as mean ± SEM. * = P < 0.05 
compared to control group. # = P < 0.05 compared to PACAP group. 
 
 
 
Figure 5. Cell type specific analysis of PACAP and VIP treatment on cystine uptake. 
(A) Cystine uptake was unaffected following PACAP (1 nM) and VIP (10 nM) treatment 
in neuronally-enriched cultures (n = 6–16). (B) Both PACAP and VIP significantly 
increased cystine uptake in astrocyte-enriched cultures (n = 8–16). (C) There was no 
affect of PACAP or VIP on microglial cystine uptake (n = 5–8). Data are expressed as 
mean ± SEM. * = P < 0.05 compared to control group. 
 
 
 
Figure 6. Cystine uptake in astrocyte-enriched glial cultures following treatment with 
increased concentrations of PACAP and VIP. In contrast to mixed cortical cultures, 
radiolabeled cystine uptake in astrocyte-enriched glial cultures was increased by both 
1 and 10 nM PACAP, while VIP treatment again showed significantly increased uptake 
at both 10 and 100 nM similar to mixed culture treatment (n = 6–16). Data are 
expressed as mean ± SEM. * = P < 0.05 compared to control group. 
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4. Discussion 
Previous reports have indicated that both neuropeptides and 
growth factors may be potential regulators of the cystine-glutamate 
antiporter, system xc− (Johnson and Johnson, 1993; Liu et al., 2012). 
The present study demonstrates that the pleiotropic neuropeptide 
PACAP is a novel regulator of system xc− activity. PACAP treatment of 
primary mixed cortical cultures in vitro for 24 hours significantly 
increased radiolabeled cystine uptake. Inhibition of system xc− via co-
administration of CPG with radiolabeled cystine eliminated cystine 
uptake almost completely in both control and PACAP-treated cultures 
indicating that PACAP facilitated cystine uptake was mediated 
specifically through system xc−. Furthermore, the increases in cystine-
glutamate exchange appear to be mediated, in part, by increased 
transcription of the specific light chain subunit of system xc−, xCT. This 
induction of cystine-glutamate exchange activity appears to be driven 
primarily via VPAC1R signaling through a PKA-dependent pathway that 
is specific to astrocytes in our primary cortical cultures. 
A concentration-response of PACAP treatment on primary mixed 
cortical cultures for 24 hours produced a unique response curve of 
cystine uptake with a significant increase at the optimal concentration 
of 1 nM, while a concentration of 10 nM PACAP did not produce any 
changes in cystine uptake (Fig. 1A). Of note, PACAP treatment can 
produce proliferation of astrocytes in vitro and a similar bell-shaped 
response curve was reported in these experiments (Hashimoto et al., 
2003; Tatsuno et al., 1996), however, our data involving radiolabeled 
cystine uptake was normalized to total protein concentration in each 
well therefore accounting for any changes in astrocyte populations. In 
addition, the increase in cystine uptake in primary mixed cortical 
cultures at 1 nM PACAP was relatively modest compared to increases 
observed in astrocyte-enriched glial cultures that possess both 
astrocytes and microglia and lack neurons (Fig. 5B) suggesting that 
PACAP-mediated regulation of system xc− is primarily driven by 
signaling on astrocytes. In support, the use of microglial cultures 
showed no significant increases in cystine uptake from either PACAP or 
VIP treatment (Fig. 5C) ruling out significant contributions of microglia 
within the astrocyte-enriched cultures. Interestingly, large increases in 
cystine uptake were observed at the 10 nM concentration of PACAP in 
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astrocyte-enriched cultures (Fig. 6), which did not occur in mixed 
cultures indicating that PACAP stimulation of neurons may evoke 
release of other factors capable of affecting cystine-glutamate 
exchange via system xc− on astrocytes. 
Effects produced by PACAP signaling are often attributed to 
PAC1R activation including the enhancement of glial sodium-dependent 
excitatory amino acid transporters (EAAT) following PACAP treatment 
of astrocyte cultures (Figiel and Engele, 2000), however, in our studies 
the PAC1R antagonist PACAP6-38 actually potentiated the effect of 1 
nM PACAP treatment in mixed cultures on cystine uptake (Fig. 4A). 
Instead, the nonspecific VIP receptor antagonist VIP6-28 and the 
VPAC1R antagonist PG 97-269 both blocked PACAP-induced increases 
in cystine uptake suggesting that regulation of system xc− in mixed 
cortical cells is achieved through VPAC1R signaling. Furthermore, a 
concentration-response of VIP treatment did not produce the same 
response profile for cystine uptake in primary mixed cortical cultures 
as PACAP (Fig. 4E), indicating that VIP-neuron interactions do not 
suppress system xc− activity, and because VIP does not bind to PAC1R, 
perhaps demonstrating a role for neuronal PAC1R activation in 
reducing cystine-glutamate exchange during prolonged treatments in 
vitro. 
PACAP and VIP are neurotrophic peptides that have numerous 
effects on both astrocyte function and glutamate homeostasis 
(Arimura et al., 1994; Brenneman et al., 1998; Figiel and Engele, 
2000; Hannibal et al., 2000; Magistretti et al., 1998; Martin et al., 
1995; Masmoudi-Kouki et al., 2011; Morio et al., 1996; Seaborn et al., 
2011; Yuhara et al., 2001). As an excitatory neuropeptide expressed 
in glutamatergic neurons, PACAP enhances both NMDA and AMPA 
currents in the hippocampus through PAC1R signaling (Costa et al., 
2009; Hannibal et al., 2000; Macdonald et al., 2005; Yaka et al., 
2003). In addition, VIP and PACAP also convey signals of metabolic 
need to astrocytes by induction of glycogenolysis (Magistretti et al., 
1998). Thus, regulation of cystine-glutamate exchange activity is yet 
another mechanism by which PACAP and/or VIP can modulate 
glutamate signaling through control of astrocyte function. Considering 
PACAP and VIP ameliorate glutamate toxicity and oxidative stress 
(Brown, 2000; Masmoudi-Kouki et al., 2011; Morio et al., 1996; Said 
et al., 1998; Shintani et al., 2005; Vaudry et al., 2002), their signaling 
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may act through augmenting system xc− activity in order to increase 
extrasynaptic glutamatergic tone on the presynaptic group II/III 
metabotropic glutamate autoreceptors, dampening the potentially 
harmful excessive synaptic release of neurotransmitter. 
Primary cortical neurons express PAC1 and VPAC2 receptor 
subtypes, while primary cortical astrocytes express all three receptor 
subtypes including VPAC1 (Grimaldi and Cavallaro, 1999). It is still 
unclear how treatment with PACAP for periods of 24 hours or more 
affects PACAP receptor signaling and expression, however, in the 
current experiments augmented system xc− activity occurs via 
activation of the VPAC1 receptor after six or more hours of treatment. 
In vivo expression of the VPAC1R is distributed throughout the central 
nervous system of rodents, with very high levels of immunoreactivity 
reported in cortical layers (Joo et al., 2004). Notably, aged rats display 
decreased VPAC1R expression in cortex, hippocampus, and amygdala 
(Joo et al., 2005), and coincidentally these same brain regions are also 
areas that are high risk for neurodegeneration, which can contribute to 
cognitive decline. Glutathione availability has also been shown to 
decline with age, and is thought to underlie the development of 
disease due to oxidative stress (Liu et al., 2004; Suh et al., 2004). 
Therefore, one contributing factor to the decline of glutathione 
production and increased incidence of cognitive decline with age may 
be the decreased expression of VPAC1R causing less cystine-glutamate 
exchange in the cognitive centers of the brain. 
Alterations in system xc− activity and expression have been 
implicated in various disease states such as gliomas, schizophrenia, 
and drug abuse (Baker et al., 2008; Baker et al., 2003; Ye et al., 
1999). Oxidative stress and glutamate dysfunction lead to the 
development of numerous pathologies, demonstrating that system xc− 
may be an attractive target for drug development. However, it should 
be noted that conflicting evidence exists regarding the phenotype of 
xCT knockout mice, where spontaneous deletion of the xCT gene 
characterized in sut/sut mutant mice results in significant brain 
atrophy (Shih et al., 2006), the genetically engineered xCT knockout 
mice do not appear to have significant behavioral or morphological 
deficits (Lewerenz et al., 2013). Furthermore, increased system xc− 
activity may produce excitotoxicity under certain circumstances such 
as in primary brain tumors (de Groot and Sontheimer, 2011), 
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interleukin-1β mediated hypoxic neuronal injury (Fogal et al., 2007; 
Jackman et al., 2010), and long-term treatment with fibroblast growth 
factor-2 (FGF-2) in vitro (Liu et al., 2014). 
The current study identifies a novel neuropeptide signal that 
regulates the function of the cystine-glutamate antiporter. PACAP/VIP 
signaling may critically modulate system xc− activity throughout the 
CNS conveying signals to astrocytes of increased activity and oxidative 
stress at the synapse. Future studies are needed to examine the 
potentially harmful affects of abnormal PACAP/VIP signaling on system 
xc− function, as well as the therapeutic potential of targeting these 
neuropeptides in order to drive system xc− activity for the treatment of 
disease. 
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